ReviewCancer immunology research2019
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.
Review in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Pooled it
- Niches in cancer: from primary tumors to metastatic disease.Journal of hematology & oncology · 2026Review
- Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation.Frontiers in immunology · 2026Review
- Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.International journal of biological sciences · 2026Review
- Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma.Nature communications · 2025Article
- Altered dynamics of T cell subsets in peripheral blood impacts disease progression in newly diagnosed multiple myeloma.Biochemistry and biophysics reports · 2025Article
- Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors.Journal for immunotherapy of cancer · 2025Article
- Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Immune checkpoint blockade in hematological malignancies: current state and future potential.Frontiers in oncology · 2024Review
- Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.Frontiers in immunology · 2023Article
- Tumor-associated macrophages in multiple myeloma: advances in biology and therapy.Journal for immunotherapy of cancer · 2022Review
- Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.Cancer research communications · 2022Article
- Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications.Frontiers in immunology · 2022Review
- The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma.Frontiers in immunology · 2022Review
- Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises.Cancers · 2021Review
- Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma.Oncogene · 2021Article
- Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.Cancers · 2021Review
- Review
- TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.Pharmaceuticals (Basel, Switzerland) · 2021Review
- CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immune checkpoints and agonists modulate ongoing, antigen-specific immune responses. Therapeutic blockade of CTLA-4, PD-1, and PD-L1 has proven to be an effective treatment approach for a subset of patients with a variety of cancers of epithelial, mesenchymal, or hematologic origin. In multiple myeloma, a B-cell lymphoid malignancy of terminally differentiated plasma cells, PD-1 pathway blockade is ineffective as a single agent. The initial promise in combination approaches utilizing anti-PD-1 with the immunomodulatory drugs, lenalidomide or pomalidomide, was not confirmed in randomized trials. Here, we explore available data for and against manipulation of the PD-1 pathway and other immune checkpoints in myeloma and highlight several promising concepts and challenges that face ongoing development of immunotherapeutics for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.